Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept in DME
NCT07096713Completed
- Sponsor
- Benha University
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of brolucizumab in diabetic macular edema (DME) (2 arms), sponsored by Benha University. Primary endpoints: Change in Best-Corrected Visual Acuity at 6 months and Change in Central Retinal Thickness at 6 months. Started Jan 2024; status: completed.
02
Drugs
brolucizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07096713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096713.